Potassium-lowering effects of sodium-zirconium cyclosilicate in the early post-transplant period.
William ShockeyJoshua J WiegelSandesh ParajuliNeetika GargKurtis J SwansonDidier A MandelbrotPublished in: Clinical transplantation (2023)
This study represents the largest investigation on the use of SZC in transplant recipients. A single 10-g dose of SZC reduced serum K+ levels in all subgroups, while the use of adjunctive K+-lowering therapies did not provide additional reduction beyond the effects of SZC. Importantly, no gastrointestinal complications were observed. These findings suggest that SZC may be a safe and promising therapeutic option for hyperkalemia management following solid organ transplantation.